European Immunization Week (EIW) aims to raise awareness of the importance of immunisation for the general health and well-being of the European and wider population.
High burden of Hepatitis B and C persists in the EU/EEA
Recent ECDC data show that despite progress in prevention and control, the hepatitis B and hepatitis C viruses still pose significant public health challenges in the EU/EEA.
Significant disruptions were observed in HIV-specific services, particularly for in-clinic and community-based HIV testing, according to an ECDC report.
Nearly 7 000 excess deaths from tuberculosis occurred in the WHO European Region from 2020 - 2022. This increased mortality would not have occurred if TB diagnosis and treatment efforts had not been disrupted during the pandemic.
The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.
In this report, we provide an overview of the data reported by countries in the EU and EEA in 2023 to describe progress towards the 2025 interim targets for hepatitis elimination as outlined in the WHO European Region Action Plan 2022–2030.
In 2022, 23 273 cases of hepatitis C were reported in 29 EU/EEA countries. Excluding countries that only reported acute cases, 23 249 cases were notified, corresponding to a crude rate of 6.2 cases per 100 000 population.
Join the ECDC Crowd and work on improving and transforming health science one task at a time with your insights on study design, statistical analysis, data collection and interpretation
About ECDC
ECDC collects, analyses and shares data on more than 50 infectious disease topics. ECDC experts assess risks to Europe and provide guidance to help countries prevent and respond to outbreaks and public health threats.